Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 340,264 shares, a decrease of 95.7% from the June 30th total of 7,845,889 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 2,998,595 shares, the short-interest ratio is currently 0.1 days.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX remained flat at $31.49 during midday trading on Friday. The business has a 50-day moving average of $31.39 and a 200 day moving average of $27.30. The company has a market cap of $3.86 billion, a PE ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals has a 12-month low of $19.05 and a 12-month high of $32.56.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. WINTON GROUP Ltd boosted its holdings in shares of Catalyst Pharmaceuticals by 546.7% during the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock valued at $8,251,000 after acquiring an additional 298,862 shares during the period. Globeflex Capital L P increased its holdings in shares of Catalyst Pharmaceuticals by 54.2% in the 1st quarter. Globeflex Capital L P now owns 450,580 shares of the biopharmaceutical company’s stock worth $11,156,000 after acquiring an additional 158,372 shares during the period. Merit Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $654,000. Wakefield Asset Management LLLP bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $1,203,000. Finally, Convergence Investment Partners LLC lifted its position in Catalyst Pharmaceuticals by 106.8% in the 1st quarter. Convergence Investment Partners LLC now owns 75,682 shares of the biopharmaceutical company’s stock valued at $1,874,000 after purchasing an additional 39,092 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CPRX has been the topic of several recent analyst reports. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).